Background: Depression affects more than 300 million people worldwide and is a leading contributor to the global disease burden. Traditional diagnostic methods, such as structured clinical interviews, are reliable but impractical for frequent or large-scale screening. Self-report tools like the Patient Health Questionnaire-8 (PHQ-8) require disclosure and clinician oversight, limiting accessibility. Recent artificial intelligence–based approaches leverage multimodal behavioral cues (linguistic, acoustic, and visual) for automated depression detection but remain constrained by limited adaptability, scarce annotated data, weak emotional expression in real-world settings, and the high computational cost of deployment of socially assistive robots (SARs). Objective: This study introduces Depression Social Assistant Robot (DEPRESAR)-Fusion, a lightweight multimodal depression detection framework designed for natural interactions with emotion-aware SARs. The objective of this study was to enhance detection accuracy in everyday conversations while addressing the challenges of data scarcity, weak emotional cues, and computational efficiency. Methods: DEPRESAR-Fusion integrates acoustic, linguistic, and visual features with an emotion-aware response module powered by large language models to adapt conversational strategies dynamically. To stimulate richer emotional expression, participants were exposed to emotionally evocative videos before SAR interactions. To overcome data scarcity, we augmented training with (1) public depression-related social media corpora and (2) synthetic samples generated via large language models. The proposed multimodal fusion architecture was evaluated on benchmark clinical datasets for both binary depression classification and PHQ-8 regression tasks. Performance was compared against prior multimodal baselines using root mean square error, mean absolute error, and standard classification metrics. Results: Participants who viewed emotional stimuli before interacting with SARs exhibited significantly higher emotional expressiveness, leading to improved model performance. Regression tasks showed lower root mean square error and mean absolute error, while classification tasks achieved significantly higher accuracy than the nonstimulus condition. DEPRESAR-Fusion outperformed prior multimodal baselines across multiple benchmark datasets, achieving state-of-the-art performance in both binary classification and PHQ-8 regression. The system maintained a lightweight architecture suitable for real-time deployment on SARs. Conclusions: DEPRESAR-Fusion demonstrates that integrating emotion induction, data augmentation, and lightweight multimodal fusion can enable accurate and scalable depression detection in naturalistic SAR interactions. By bridging the gap between structured clinical assessments and everyday conversations, this approach highlights the potential of SAR-based systems as nonintrusive, artificial intelligence–driven tools for proactive mental health support.
<img src="https://jmir-production.s3.us-east-2.amazonaws.com/thumbs/79059e30c7d6ea717d347b5b83aa07e2" />
Enhancing Sleep and Mental Health: Longitudinal, Observational, Real-World Study From a Digital Mental Health Platform
The Effectiveness and Mechanisms of Action of App-Based Interventions for Improving Mental Health and Workplace Well-Being: Randomized Controlled Trial
Background: Depression is the most common mental health disorder worldwide and frequently leads to workplace absence. As face-to-face treatment can be difficult to access, app-based interventions are a popular solution, although their effectiveness in working populations and their mechanisms of action are unclear. Deficits in executive function may contribute to the onset and maintenance of depression, and executive function training is proposed to improve symptoms by enhancing executive function. Responders to cognitive behavioral therapy (CBT) show improvements in executive function, suggesting that this may be one mechanism of action. Objective: This study investigated the effectiveness of app-based interventions (executive function or CBT-based) for reducing depressive and anxiety symptoms and improving workplace well-being, and assessed whether changes in executive function mediated improvements. Methods: A total of 228 participants (147 female participants) with mild-to-moderate symptoms of depression and anxiety were recruited online and randomly assigned to a waitlist control group, an executive function training group (NeuroNation app, Synaptikon GmbH), or a self-guided CBT group (Moodfit app, Roble Ridge LLC) for a 4-week intervention period. Participants assigned to the active intervention groups were asked to use their apps a minimum of 21 times during the intervention. Participants completed measures of depressive symptoms, anxiety symptoms, and workplace well-being, and a working memory task at baseline, postintervention, and follow-up (12 weeks). Results: Executive function training reduced anxiety (β=−2.79; =.004) and depressive (β=−2.77; =.02) symptoms at follow-up but not at postintervention, and it did not affect workplace well-being. There were no reductions in depressive or anxiety symptoms in the self-guided CBT group, though workplace well-being was improved at postintervention (β=3.72; =.02) and follow-up (β=4.46; =.02). Improvements in executive function did not mediate intervention-related changes in symptoms or workplace well-being. Self-reported adherence rates were high (executive function training: 48/54, 89%; self-guided CBT: 52/54, 96%), although attrition was high at follow-up (58% missing). Conclusions: These results suggest that app-based executive function training may be effective at managing symptoms of anxiety and depression in a working population, while self-guided CBT apps may improve workplace well-being. However, improving executive function did not appear to be a mechanism of action of either intervention. Trial Registration: ISRCTN 12730006; https://www.isrctn.com/ISRCTN12730006
<img src="https://jmir-production.s3.us-east-2.amazonaws.com/thumbs/97ff2f6a5aa1b4552bcc78ed572308d4" />
Trump administration warns against using federal dollars on fentanyl test strips
The Trump administration is doubling down on its opposition to harm reduction services for people who use illicit drugs.
In an open letter on April 24, the federal agency overseeing addiction and mental health policy warned its grantees against using federal funds to buy harm reduction supplies including sterile syringes and pipes, or to distribute test strips for common drug supply adulterants like fentanyl, xylazine, and medetomidine.
How adolescent cannabis use reshapes the developing brain — a systematic review
Electrophysiological and morphological alteration in the visual pathway of children with attention-deficit/hyperactivity disorder
From collective restriction to critical action: the indirect effects of critical motivation and radical hope
Ngā māuiui kai: a cross-sectional study of elevated eating disorder risk and related experiences among trans people in Aotearoa
3 things to know before Tardive Dyskinesia Awareness Week
The post 3 things to know before Tardive Dyskinesia Awareness Week appeared first on Mental Health America.
3 common myths about workplace mental health and wellness
The post 3 common myths about workplace mental health and wellness appeared first on Mental Health America.

